{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 56,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The chart uses a visual metaphor of a 'ceiling' (the 40% remission line) and an arrow to indicate the desired shift in therapeutic performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/8",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "UC Maintenance Remission Rates (%) vs Maintenance dosing frequency (weeks)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c374dfee-ebca-40ed-ac5c-fb1570beabb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Summary data for select agents that randomize patients post response to induction; data from labels, company reports. Vedolizumab approved in US as Q8W IV – Q2W SC approval pending following CRL in 2019. TL1A maintenance data not available. Orals not shown (pbo-adj maintenance remission rates): Jaks - tofacitinib (27%), upadacitinib (30% 15mg, 40% 30mg); S1Ps: ozanimod (19%); etrasimod (25% - P3 Treat-through design).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38868dc8-110f-4ca2-8650-13af88ebfb41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f29e27a1-9e10-40ab-9532-cbe972188af2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "bc506c21-6819-4419-b132-7afa4a88234c",
      "evidence": "Contrasts current SOC with future target to define the market gap.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "50cfb41c-c55f-4d71-bad7-662cc5ddaf6c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the problem and the need for new approaches",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "2c2ea794-d311-4166-8444-be0ff8d81ce6",
      "evidence": "The document uses the golden circle to explain the company's mission and vision",
      "position": 0,
      "objective": "Why is this important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}